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Abstract Infectious complications after allogeneic
haematopoietic stem cell transplantation (allo-HCT) remain
a clinical challenge. This is a guideline provided by the
AGIHO (Infectious Diseases Working Group) of the DGHO
(German Society for Hematology and Medical Oncology). A
core group of experts prepared a preliminary guideline, which
was discussed, reviewed, and approved by the entire working
group. The guideline provides clinical recommendations for
the preventive management including prophylactic treatment
of viral, bacterial, parasitic, and fungal diseases. The guideline
focuses on antimicrobial agents but includes recommenda-
tions on the use of vaccinations. This is the updated version
of the AGHIO guideline in the field of allogeneic
haematopoietic stem cell transplantation utilizing methods ac-
cording to evidence-based medicine criteria.
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Introduction
Infectious complications remain a clinical challenge in the
setting of allogeneic haematopoietic stem cell transplantation
(allo-HCT). Particular during the early phase after allo-HCT,
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mortality rates for infections are high [1, 2]. After the first
publication of recommendations from our group in 2003, [3]
numerous new results of trials have been published and im-
plemented into daily patient care. With this updated guideline,
AGIHO (Infectious Diseases Working Group) of the DGHO
(German Society for Hematology and Medical Oncology)
pursues a step forward to include the entire patient history
up right from the beginning of the preparation of patients
through the entire post allo-HCT time period.
This guideline focuses on the adult patient population only
and is partitioned into four parts: (a) general precautions and
prevention measures, (b) pre-transplantation (screening)
phase, (c) prophylactic treatment, and (d) immunization
strategies.
Methods
Several steps were undertaken to develop the updated guide-
line: The first step was defining a group of specialists. They
were enlisted by the AGIHO of the DGHO with a designated
coordinator. The coordinator was responsible to manage the
efforts of the group. The group of authors consisted of 14
certified internists, including 13 certified haematologists, and
5 certified infectious diseases specialists. Four authors are
triple certified in internal medicine, infectious diseases, and
haematology/oncology.
Predefined topics were elaborated by subgroups and then
presented to the entire group for discussions. This included
several face-to-face meetings, which were complemented by
conference calls. Once the group had consensus with their
results, the preliminary recommendations of the group were
presented to the entire AGIHO assembly for review, discus-
sions, modification, and final approval. All recommendations
were made on the basis of available data providing evidence-
based medicine. The guideline utilized the latest version of the
strength of recommendation and quality of evidence pub-
lished by the ESCMID (Table 1) [4]. Specific topics related
to cord blood or haplo-identical transplant recipients are not
addressed by this guideline.
General precautions
An allo-HCT requires certain assessment procedures, which
are basically standardized (e.g. JACIE by the EBMT). Herein,
we touch off on a few basic standardized requirements.
Patients’ rooms should be equipped with air-filtered sys-
tems to keep spore counts low and, thus, preventing nosoco-
mial fungal diseases (BII) [5–9]. Further, nearby construction
activities should be kept to a minimum (AII).[10] Isolation of
the stem cell recipients in a single hospital room under condi-
tions of laminar airflow or positive pressure HEPA filtration
(>12 exchanges per hour) is generally recommended.
However, randomized controlled trials focusing on HEPA
filter efficacy against viral infections are lacking. Especially
respiratory virus outbreaks, including seasonal pathogens
such as respiratory syncytial virus (RSV) and influenza, are
not prevented by HEPA filtrations [11]. Genotyping of RSV
outbreaks demonstrated that more than two thirds were hos-
pital acquired [12–15]. These results underscored the impor-
tant necessity of infection control measures (i.e. barrier pre-
cautions) to prevent exposure directly at the patients’ site
(AII).
Some debate usually arises on the topic of appropriate di-
etary needs for patients after allo-HCT. The rule of thumb
Bcook it, peal it, or forget it^ is easy to understand.
However, there is a lack of appropriate literature on this spe-
cific topic. On the other hand, the evidence is clearer for the
prevention of specific infections, e.g. listeria or other agents
Table 1 Strength of the AGIHO
(DGHO) and DAG-KBT
recommendation and quality of
evidence (modified according to
[4])
Strength of a recommendation
Grade A AGIHO strongly supports a recommendation for use
Grade B AGIHO moderately supports a recommendation for use
Grade C AGIHO marginally supports a recommendation for use
Grade D AGIHO supports a recommendation against use
Quality of evidence
Level I Evidence from at least 1 properly designed randomized, controlled trial
Level IIa Evidence from at least 1 well-designed clinical trial, without
randomization; from cohort or case-controlled analytic studies
(preferably from >1 centre); from multiple time series; or from
dramatic results of uncontrolled experiments
Level III Evidence from opinions of respected authorities, based on clinical
experience, descriptive case studies
a Added index: r: meta-analysis (or systematic review of RCT); t: transferred evidence i.e., results from different
patients ‘cohorts’ or similar immune status situation; h: comparator group: historical control; u: uncontrolled trials;
a: published abstract (presented at an international symposium or meeting)
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causing infectious diarrhea (BII) [16, 17]. Contact precautions
and hand disinfection (incl. repeated teaching on this matter)
can prevent nosocomial infection (AII) [18]. Healthcare
workers (HCW) with transmissible diseases (e.g. herpes, in-
fectious gastroenteritis, respiratory tract infections) should be
restrained from direct patient care to prevent any nosocomial
spread of their disease (AIII) [19]. Some hospital facilities
have recovered microbes (e.g. Legionella spp.) from their
drinking water. In order to prevent transmission in high-risk
patients, water filters provide a protective solution though reg-
ular testing remains a necessity (AII) [20–22].
Pre-transplantation (screening) phase
A comprehensive pre-transplant assessment of the allo-HCT
recipient for infectious complications is a valuable tool to
identify patients at increased risk for distinct infectious
diseases.
Syphilis, tuberculosis, Toxoplasma gondii, HIV, hepatitis B
and C viruses, and Herpes viridae usually persist lifelong in
the host after primary infection and can be reactivated under
certain conditions. As a consequence, all candidates for allo-
HCTshould undergo a test for IgG antibodies specific for viral
diseases, syphilis, and toxoplasmosis. False negative results
particularly could occur in the context of CLL, multiple my-
eloma, previous antibody treatment (e.g. rituximab), or might
be false positive after IVIG application or blood product trans-
fusion. In any case, all patients tested IgG-seronegative strictly
remain on preventive measures to avoid de novo infection
prior to allo-HCT and afterwards.
Specific viruses
Herpes viridae
All candidates for allo-HCT should be tested for CMV, EBV,
and VZV IgG antibodies to determine their risk for reactiva-
tion or de novo infection (AIII) [23–25]. Due to the high
prevalence of HSV in the patient population, further antibody
testing for HSV is not mandatory (CIIt) [26].
Hepatitis B
Prior to allo-HCT, besides hepatitis B virus (HBV) antibody
panels, additional testing for hepatitis B surface antigen
(HBsAg) should be performed [27, 28]. If tested positive for
HBsAg or for anti-HBc, further HBV-DNA assessment for
active replication is crucial (AII). If considered to be diag-
nosed with active hepatitis (e.g. viral replication), initiation
of antiviral treatment prior to allo-HCT should be considered
(AIII) [29].
There is a reported risk of up to 50 % for reverse serocon-
version after allo-HCT if a patient is anti-HBc positive but has
no detectable viral replication (resolved HBV infection)
[30–32]. HBV-vaccination after allo-HCT might alleviate this
risk [33].
Hepatitis C
Serologic testing for hepatitis C virus (HCV) is recommended.
Serologically positive patients should receive quantitative
testing for HCV-RNA viral load (AIII). Patients with chronic
hepatitis C should receive a further diagnostic assessment,
e.g., fibroscan or a liver biopsy to rule out liver fibrosis or
cirrhosis. In case of liver cirrhosis or fibrosis, the conditioning
regimen should try to avoid TBI, oral busulfan, or cyclophos-
phamide to minimize risk of hepatic sinusoidal occlusion syn-
drome (SOS) (BIII) [34–37].
Hepatitis E
Hepatitis E virus (HEV) is detected in immunocompromised
patients. Limited information is available on the real incidence
of HEV infection in recipients of allo-HCT [38, 39]. Mostly
self-limited reactivation cases are published though chronic
forms have been described as well. Serologic testing for
HEV prior to allo-HCT is recommended (BIII). HEV should
be considered as a differential diagnosis in patients after allo-
HCTwith elevated liver function tests [39–41].
HIV
HIV testing prior to allo-HCT is recommended. HIV-infected
patients should be carefully evaluated for allo-HCT. Though
HIV seropositivity per se is not a contraindication for allo-
HCT [42]. If allo-HCT seems feasible, a donor screening for
CCR5-Delta 32 deletion could be considered in patients with
CCR5 tropism to potentially control HIV infection post-allo-
HCT (BIII) [43, 44]. Toxicity permitting, antiretroviral thera-
py should be continued throughout of the post-transplantation
phase (AII) [45]. However, recurring interruptions with low
drug levels may induce viral resistance, and an interrupted
treatment should not be reinstated until the patient has suffi-
ciently recovered to allow stable tablet intake (BIII).
Syphilis
Serologic testing for syphilis is recommended. Frequently
TPHA/TPPA or VDRL are utilized. Important are the combi-
nations of nontreponemal (e.g. VDRL) and treponemal tests.
If a nontreponemal test is positive, confirmation of infection
with treponemal test (e.g. TPPA or TP-EIA) should be per-
formed. In case of an active infection or unclear whether the
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patient received an adequate treatment in the past, a treatment
with penicillin should be instituted (BIII) [46].
Toxoplasmosis
All candidates for allo-HCT should undergo serologic testing
for toxoplasmosis. If the serology testing for toxoplasmosis
IgG is positive, patients have a risk of toxoplasmosis reacti-
vation, especially if the donor is serologically negative for
toxoplasmosis [47]. Some centres propagate regular PCR test-
ing [48]. Since the incidence in Europe is very low, regular
toxoplasmosis DNA through PCR screening is not recom-
mended (DIII). This is of course different in patients with
clinical symptoms.
Tuberculosis
Thorough evaluation of the medical history can identify pa-
tients at risk for latent or active tuberculosis infection (AIII).
As most candidates have received chemotherapy or immuno-
suppressive treatment prior to evaluation for allo-HCT, a tu-
berculin skin test might be false negative and therefore cannot
be recommended in this setting (DIII). If the medical history
is suggestive of prior tuberculosis exposure, an interferon-
gamma-release assay (IGRA) can be considered (BIII) [49].
However, a reduced sensitivity in immunocompromised pa-
tients has been demonstrated as well [50, 51].
Prophylaxis and prevention
Prevention of bacterial infections (screening for bacterial
colonization)
In this era of easy accessibility of antibiotics, clinicians are
facing the growing challenge of multi-resistant bacteria (e.g.
vancomycin-resistant Enterococci (VRE), methicillin-
resistant Staphylococcus aureus (MRSA), extended-
spectrum beta-lactamase producing bacteria (ESBL),
metal lo-ß - lactamase-producing bacter ia (MBL)) .
Colonization with certain multi-resistant bacteria is predictive
for developing bloodstream infection, and knowledge of col-
onization status may therefore guide empirical antibiotic treat-
ment, although this strategy has not been demonstrated to
improve outcomes [52, 53]. We recommend screening proce-
dures for multi-resistant bacteria, especially in institutions
with a known high prevalence (BII) [54, 55]. Since the sensi-
tivity of the screening methods is low, repeated testing (e.g.
weekly rectal swabs) would be required [56–58]. Contact pre-
cautions between medical staff and patients remain to be
necessary and separate sanitary facilities need to be
guaranteed to exclude cross-patient transfer of multi-
resistant bacteria [59, 60].
Antibiotic prophylaxis (e.g. ciprofloxacin) demonstrated
its efficacy by reducing the incidence of Gram-negative sepsis
during neutropenia without any significant change in mortal-
ity [61, 62]. All-cause mortality was reduced only in meta-
analysis [63]. At institutions with a low rate of multi-resistant
gram-negative bacteria, antibacterial prophylaxis remains a
reasonable choice to reduce the incidence of Gram-negative
sepsis during neutropenia (AIIr) [62, 64–67]. Encapsulated
bacteria such as Streptococcus pneumoniae or Haemophilus
influenzae often cause severe bacterial infections in the late
phase after transplantation [68–70]. In patients with chronic
GVHD (graft-versus-host disease) on immunosuppressive
therapy, antibiotic prophylaxis against these bacteria for dis-
ease prevention might be useful until immunizations can be
applied (BIII). Antibiotic selection should be guided by local
antibiotic resistance patterns. In patients without chronic
GVHD, systemic antibiotic prophylaxis is not recommended
after reconstitution of the neutrophils (DIII).
The value of selective gut decontamination is frequently
debated and the literature points out that sepsis rates are in-
creased and mortality outcomes were significantly worse in
patients with lower intestinal diversity; therefore, no recom-
mendation was made [71–74].
Prophylaxis against Pneumocystis pneumonia
Pneumocystis jirovecii (previously named Pneumocystis
carinii) pneumonia has been noted in allo-HCT recipients
with an incidence of approximately 5–16 % without adequate
prophylaxis and occurred at a median of 9 weeks after allo-
HCT. Despite intensive treatment, mortality rates are as high
as 89 % during the first 6 months and approximately 40 %
after the first 6 months following allo-HCT [75, 76].
Prophylaxis against Pneumocystis jirovecii pneumonia is
recommended for at least first 6 months after allo-HCT to
prevent Pneumocystis jirovecii pneumonia-associated death
(AIIt). However, patients might require prophylaxis for
prolonged periods of time. Recommended prophylactic regi-
mens are similar to regimens in HIV/AIDS patients.
Therefore, patients on immunosuppressive medications or ac-
tive GVHD should remain on prophylaxis [77]. Once immu-
nosuppressive medications are discontinued or no active
GVHD is noted, prophylaxis may be discontinued assuming
a CD4+/CD3+ lymphocyte count of 200/μL or higher (BIIt).
Thus monitoring of CD4+/CD3+ lymphocytes could be con-
tinued until the threshold is confirmed by repeated testing
(BIIt) [78]. The CD4
+/CD3+ lymphocyte count of 200/μL
as a discontinuation criterion is not confirmed in the allogene-
ic setting, and therefore, an individual decision to discontinue
can be considered (CIII).
The prophylactic treatment of choice is the fixed combina-
tion of trimethoprim (80 mg) and sulfamethoxazole (400 mg)
once daily thrice weekly (AIIt) [79–82]. In case of intolerance
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to the trimethoprim/sulfamethoxazole therapy, aerosolized
pentamidine (300 mg) every 4 weeks (BIIt) or atovaquone
(750 or 1500 mg daily) (BIIt) is recommended [83–89].
Dapsone (100 mg) cannot be recommended (DIIt) [90].
Protective efficacy against Pneumocystis appears to be less
with these alternative drugs compared to trimethoprim/
sulfamethoxazole [84, 86, 90–93].
Antifungal prophylaxis in allo-HCT
Invasive fungal diseases (IFDs) are severe complications as-
sociated with prolonged hospital length of stay, costs, long-
term treatment, and high mortality [94]. Approximately two
thirds of the IFD develop in allo-HCT patients after leukocyte
recovery [95, 96]. Furthermore, intensifying immunosuppres-
sion for treatment of transplant rejection or GvHD and CMV
infection impose an imminent risk for IFD [97, 98].
The incidence of invasive aspergillosis (IA) varies between
reports and may reach 23 % [94, 99]. Primary prophylaxis is
highly recommended since diagnostic tools do not present
with sufficient sensitivity numbers. This is mirrored in studies
with a significant number of post-mortem diagnoses of fungal
diseases [100–102]. In patients diagnosed with IA, mortality
rates of up to 60 % have been reported despite adequate treat-
ment [103]. Secondary prophylaxis is recommended prior to
allo-HCT (BII) [104].
Invasive candidiasis, predominantly manifesting as
candidemia, is the second most frequent IFD in allo-HCT
patients. Invasive candidiasis/candidemia typically manifests
in patients with underlying conditions after being exposed to
additional risk factors, e.g. intravascular devices, broad-
spectrum antibiotic treatment, total parenteral nutrition, or
Candida colonization [105–107].
The currently largest cohort of IFDs shows an 8 % share of
mucormycosis in all IFDs in allo-HCT, followed by a number
of other rare mould infections [94]. Approximately half of the
patients diagnosed with mucormycosis are patients after allo-
HCT [108]. The share of rare IFDs like those caused by the
order of Mucorales or Fusarium spp. appear to be increasing
[94, 109]. Newer agents like isavuconazole demonstrated fa-
vorable response rates in primary treatment against moulds;
however, larger prophylaxis studies are still needed
[110–112].
In Table 2, prophylactic recommendations are summarized.
Our group recently published recommendations for the treat-
ment (i.e. targeted therapy) of fungal diseases [113].
Herpes simplex virus 1/2 prevention
Herpes viridae persist in the host after primary infection. Up
to 80 % of adults are HSV-seropositive and especially during
immunosuppression HSV may begin to replicate. Without
prophylaxis allo-HCT recipients have a risk of approximately
80 % to reactivate during the early phase mainly during the
first 4 weeks after allo-HCT [19, 137, 138]. Dissemination
may lead to severe illness with substantial morbidity and mor-
tality. As a consequence, patients should receive acyclovir
early on for the prevention of disease to reduce mortality
(AI) [138–141] (Table 3).
The duration of prophylaxis should last for up to 30 days
after allo-HCT (AI) [139, 141]. However, exceptions are de-
fined by recurrent episodes of HSV disease or risk of Varicella
zoster disease. In these situations, duration of acyclovir pro-
phylaxis to prevent disease is prolonged to a year or longer
especially during intensified immunosuppressive therapy
(BII) [142].
Resistance to acyclovir is a rare event and mainly
caused by reduced activity or mutations of viral thymi-
dine kinase resulting in reduced activation of acyclovir
in infected cells [143, 144]. Breakthrough infections are
noted but are usually described as clinically resistant
since prophylaxis failure is explainable by decreased
bioavailability of acyclovir. In cases of real acyclovir-
resistant HSV, foscarnet susceptibility remains, and this
agent is considered as an alternative treatment option
for acyclovir-resistant disease (BII). However, it cannot
be recommended for routine prophylaxis due to its sig-
nificant toxicity (DIII) [145].
It is presumed that valacyclovir and famciclovir are effec-
tive for the prevention of HSVreactivation; however, there are
no clinical trials in allo-HCT to better support a recommenda-
tion (CIII) [146, 147].
Varicella zoster virus prevention
Since Varicella zoster virus (VZV) is highly contagious, pa-
tients with VZV disease should be isolated to prevent noso-
comial spreading of viruses until all lesions are crusted (AIII)
[148, 149]. Patients should be informed of the easy transmis-
sion of VZV. Allo-HCT recipients without adequate antiviral
prophylaxis are at risk for disease, since up to two thirds de-
velop herpes zoster, which mainly occurs 3 to 12 months after
allo-HCT [150]. VZV seronegative family members,
healthcare workers, other contact persons of allo-HCT recipi-
ents, or children without a history of Varicella or immuniza-
tion, should be advised to receive a vaccination against VZV
ideally at least 4 weeks prior to planned allo-HCT (BIII)
[151].
Primary infection is rare and is associated with a
high rate of mortality caused by frequent dissemination
(e.g. encephalitis, pneumonia, viscera, or hepatitis) [150,
152, 153]. Therefore, exposure of seronegative recipi-
ents to chickenpox, zoster or vaccinated persons who
experience a rash after vaccination should be avoided
to prevent primary disease or VZV-associated death
(BIII). If exposure to persons with chickenpox or zoster
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occu r s , pas s ive immuniza t ion wi th an t i -VZV
hyperimmunoglobulin (Ig) within 96 h after exposure
is considered optional (CIII), as efficacy has not been
proven [154, 155]. Antiviral therapy with valacyclovir
1 g po tid or acyclovir 800 mg qid should be adminis-
tered (BIII) immediately to prevent disease in seroneg-
ative recipients.
Main antiviral prophylaxis recommendations are summa-
rized in Table 3. Various authors [156–159] noted that even
prolonged administration for approximately 1 year or longer is
considered safe and there was no higher incidence of disease
after drug discontinuation. Longer than 12-month periods ap-
pears to be beneficial as long as patients remain on intensified
immunosuppressive therapy (BIII).
If resistance to acyclovir is suspected, foscarnet or
cidofovir are alternative agents (BIII) [160]. Brivudine is con-
traindicated in patients receiving 5-fluoropyrimidine deriva-
tives and was not assessed in immunocompromised patients
( D I I I ) . ( h t t p : / / www. b f a r m . d e / S h a r e d D o c s /
Risikoinformationen/Pharmakovigilanz/EN/RHB/2012/rhb-
zostex.html, last accessed May 1, 2016)
CMV disease prevention
All CMV-seronegative recipients ideally should receive a
CMV-seronegative donor graft to prevent infection and reduce
mortality (AII) [25, 161, 162]. To further prevent disease,
CMV-seronegative recipients transplanted from a negative do-
nor should only receive blood products from CMV-
seronegative donors upon availability. Blood banks without
a sufficient pool of CMV-negative donors should deliver only
leukocyte-depleted red blood cells and thrombocytes (AII)
[163]. However, data from various studies suggest if blood
products are leukocytes reduced, testing for CMV-negative
blood products is not needed for HSCT recipients (AII)
[163–165]. Noteworthy, irradiation to prevent transfusion-
associated GvHD does not inactivate CMV [164, 166–170].
Special risk factors for CMV infection or disease are Tcell-
depleted graft, HLA-mismatched transplantation, steroid
treatment, and acute or chronic GvHD [171–173]. All patients
at risk for CMV disease should be screened regularly for pp65
antigenemia or by nucleic acid detection methods after allo-
HCT (AII) [174].
Table 2 Antifungal prophylaxis
Intention Intervention SoR QoE Comments Ref
Prevent mould infection in
patients without GvHD, day 1–100
Voriconazole 200 mg bid
oral or ivb
C I No difference seen in the trial in
comparison to fluconazole
[114]
Posaconazole (suspension)
200 mg tidb
B IIt Improved overall survival in AML/MDS
induction during neutropenia, new
formulations (tablet and iv, 300 mg qid)
provide a better bioavailability
[115–117]
Micafungin 50 mg/day C I Only during neutropenia, morbidity advantage [118]
Itraconazole suspension
2.5–7.5 mg/kg or capsules
C I Administered up to 180 days if GVHD was
diagnosed; higher toxicity in comparison
to fluconazole, TDM: cutoff at 500 mg/mL (AII)
[119–121]
Prevent invasive Candida
disease in patients without
GvHD, day 1–100
Fluconazole 400 mg/day A I Improved survival, note rising incidence of
resistant Candida species since studies
were published
[122–124]
Voriconazole 200 mg bid
oral or ivb
B IIt Also active against moulds, but no difference
seen in the trial between voriconazole and
fluconazole
[114]
Posaconazole (suspension)
200 mg tidb
B IIt Also effective against moulds, new formulations
(tablet and iv, 300 mg qd) provide a better
bioavailability
[115, 117]
Micafungin 50 mg/day B IIt Also effective against moulds, only during
neutropenia, morbidity advantage
[118]
Itraconazole suspension
2.5–7.5 mg/kg or capsulesb
C I See above [119–121]
Prevent invasive Aspergillosis
during GvHD
Posaconazole (suspension)
200 mg tidb
A I improved survival (lower attributable mortality),
new formulations (tablet and iv, 300 mg qd)
provide a better bioavailability
[117, 125]
Prevent fungal disease relapse
(previous IFD)
Voriconazoleb B II considered as secondary antifungal prophylaxis,
dosages as above
[126]
Caspofungin, posaconazole B III [127, 128]
Prevent fungal diseasesa Amphotericin B deoxycholate D II Inacceptable toxicity [129–131]
a other formulations and various dosages and application regimens of Amphotericin B have been evaluated with different results in small studies, all
would need further evaluation to provide any kind of recommendation [132–134]
b Consider TDM, serum levels of efficacy in prophylaxis are still debated, e.g. posaconazole [135]
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The current standard to improvemorbidity and lowermortality
is the early initiation of a preemptive therapy against CMV (AII)
[174]. Duration of screening is usually defined by the time period
of the application of immunosuppressive agents or GVHD.
Anti-CMV prophylaxis can only be considered as an option.
The long-term administration of ganciclovir resulted in a delay of
recovery from CMV-specific T cell immunity [175].
Valganciclovir is so far not officially approved in allo-HCT pa-
tients but has been applied in randomized trials [176, 177]. In a
randomized controlled trial, valganciclovir prophylaxis was not
superior in reducing the incidence of CMV disease or death
when compared with PCR-guided preemptive therapy. Delay
in virus-specific Tcell reconstitutionwas not observed in patients
receiving prophylaxis [177]. Administration of human immune
Table 3 Antiviral prophylaxis
Intention Intervention SoR QoE Comments Ref
HSV
Prevent HSV disease Acyclovir 400 mg tid/day A II Up to 30 days post allo-HCT
(various dosages)
[139, 141,
233]
Valacyclovir 500 mg bid /day A II [234]
Acyclovir any dosage D III Beyond 30 days if patient is
also VZV seronegative
VZV
VZV disease prevention in
VZV seropositive recipients
Acyclovir 800 mg bid A I Up to 1 year after allo-HCT [156]
Acyclovir 400 mg/day B II [158, 159,
235]
Valacyclovir 500 mg bid B II [236, 237]
Acyclovir 200 mg/day B II More than 365 days if continued on
immunosuppressive therapy
[233, 238]
Prevent VZV in seronegative patients No prophylaxis C III
Prevent VZV in seronegative
patients if exposed
Passive immunization C IIt Within 96 h post exposure, optional [155]
Acyclovir or other VZV-active an-
tiviral
C III If patient is not on acyclovir
(or any other VZVactive
antiviral), a short duration of
therapy is an option.
Prevent VZV disease after exposure Vaccination – – No data to provide recommendation
CMV
Preemptive strategy recommended
over prophylaxis/treatment
Ganciclovir, valganciclovir,
or foscarnet
A I [177,
239–242]
Reduce incidence of CMV infection/
disease, if a center does not follow a
preemptive strategy
Long term acyclovir 800 mg/day C II [180]
Valacyclovir 500 mg qid/day B I [182]
Ganciclovir 2.5–5 mg/kg bid/day C II Caution: myelotoxicity [243, 244]
Valganciclovir 900 mg bid A II Caution: myelotoxicity [177]
CMV-specific CTLs C II Not available at every site
(considered experimental)
[245]
HBV
Prevent disease in HBsAG
seropositive recipients
Lamivudine 100 mg/day A II Monitor HBVDNA closely, duration
until anti-HBs is detected
(and HBV-DNA is negative)
[210, 246,
247]
Entecavir 0.5–1.0 mg/day A II [248–250]
Tenofovir 245 mg/day C III [251, 252]
Prevent disease in HBsAG seropositive
recipients with HBsAG seronegative donors
Additionally vaccinate donor B III Requires long term planning [253]
Prevent reactivation in recipients who are
anti-HBcAG seropositive, DNA viral load:
positive
Lamivudine 100 mg/day B III [209]
Prevent reactivation and disease in recipients
who are anti-HBcAG seropositive,
DNA viral load: negative
Lamivudine 100 mg/day C III
HBV-DNA/HBsAG monitoring B III [254]
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globulins for prophylaxis or therapy of CMVdisease is generally
not recommended (DII) [178, 179]. Some investigators pub-
lished efficacy of high-dose acyclovir or its prodrug valacyclovir
in the prevention of CMV disease [180–183]. However, acyclo-
vir failed to prevent CMV disease in autologous transplantation
and therefore, is not recommended for prophylaxis (DIII) [184].
Newer antiviral agents have been evaluatedmainly in phase II
trials. Maribavir, an oral antiviral agent was studied for prophy-
laxis. Maribavir inhibits the UL97 viral protein-kinase of human
CMV. Despite promising results in a phase II study, a phase III
study could not confirm a benefit [185–187]. Another antiviral
agent named CMX001 is an orally bioavailable lipid acyclic
nucleoside phosphonate and is converted intracellularly to
cidofovir diphosphate. Brincidofovir (CMX001) is active in vitro
against CMV, including ganciclovir-resistant strains and was
assessed in a phase II trial with promising results in prophylaxis
[188]. Letermovir (previously known as AIC246) is another anti-
CMVagent with a novel mechanism of action targeting the viral
terminase subunit pUL56, a component of the terminase com-
plex. This agent demonstrated dose-dependent prophylactic effi-
cacy in a phase II trial [189]. If the ongoing phase III trials
confirm these results, a paradigm shift may occur in the future.
New DNA-based vaccination strategies against CMV are
being evaluated in clinical trials [190].
Main antiviral recommendations are noted in Table 3.
Epstein-Barr virus disease prevention
Factors associated with an enhanced risk for Epstein-Barr virus
(EBV) replication and therefore infection after allo-HCT are a
selective Tcell depletion of the graft, a HLA-mismatched trans-
plantation, the choice of an unrelated donor (especially haplo-
identical transplant recipients), and the use of T cell depleting
antibodies, e.g. alemtuzumab or ATG during conditioning [191,
192]. Early EBV-disease after transplantation is extremely rare.
Primary or secondary prophylactic use of antiviral agents is not
effective against EBV and therefore not recommended (DII)
[193, 194]. Close EBV viral load monitoring and rituximab
application can be considered as a preemptive therapeutic ap-
proach for the prevention of EBV-associated PTLD after allo-
HCT in special high-risk patients (CIII) [195–197]. Still con-
sidered experimental is the application of cytotoxic T cells for
the prevention and treatment of Epstein-Barr virus-induced
lymphoma in allogeneic transplant recipients [198, 199].
Toxoplasmosis prophylaxis
Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis,
administered to most transplant patients to prevent
Pneumocystis jirovecii pneumonia, is also efficacious in
preventing toxoplasmosis disease [200, 201].
Clinical reactivation of toxoplasmosis may occur in the late
phase after transplantation in seropositive patients under im-
munosuppression. However, the risk is considerably low and
no primary prophylaxis is recommended (DIII) [47, 202,
203]. After a successful therapy of toxoplasmosis, secondary
prophylaxis should be administered for at least 3 months
(AIIt) [204–206] (Table 4).
Hepatitis A prevention
The incidence of infections due to hepatitis A varies widely.
Prevention of hepatitis A by vaccination of seronegative pa-
tients or donors follows general vaccination recommenda-
tions. A previous exposure to hepatitis A has no impact on
transplant-related complications, thus only serologic testing is
recommended. In case of IgM seropositivity of the donor and/
or recipient, allo-HCTmight be postponed since a high risk of
transmission or hepatic complications are associated with
acute hepatitis A. Additional prevention of infection of the
recipient can be achieved by avoiding potentially contaminat-
ed food. If exposed, passive immunization has been discussed
controversially even in non-transplant patients.
Following patients’ post allo-HCT, a continuous loss of
acquired hepatitis A antibodies has been described over a
median time of 48 months, especially in those older than
18 years. Thus, hepatitis Avaccination should be recommend-
ed later in adult transplanted patients at risk (BIIt) [207].
Hepatitis B prevention (Table 3)
Hepatitis B infection or reactivation contributes to liver-related
morbidity and mortality. This is a frequent problem, which oc-
curs in 21–53 % of patients with immunosuppression [208],
Table 4 Secondary prophylaxis after toxoplasmosis disease
Intention Intervention SoR QoE Comments Ref
To prevent relapse
of CNS toxoplasmosis
Pyrimethamine (25 mg/day)a +
sulfadiazine (orally, 30 mg/kg/d)
A IIt Minimum duration for 3 months,
many cases longer
[204, 206]
Pyrimethamine (25 mg/d)a + clindamycin
(intravenously, 1200 mg/d)
B IIt [255–257]
Atovaquone 750 mg qid B IIt In patients intolerant to conventional
toxoplasmic encephalitis therapies
[206]
a Should be combined with folinic acid
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especially after conditioning regimens containing alemtuzumab
[209]. The goal is to avoid impairment of liver function, fulmi-
nant liver failure, hepatic sinusoidal obstruction syndrome
(SOS), cirrhosis, or even hepatocellular cancer [210].
Preferably, HBsAG-negative donors should be selected.
However, if no other HLA-compatible donor is available, a
positive donor for transplantation is not absolutely contraindi-
cated (BIII). Although transplantation of HBV-negative patient
with stem cells from an infected donor (HBsAG positive) is
associated with a high risk of transmission, some patients de-
velop chronic hepatitis B [210]. Donors with active HBV (DNA
detection) should receive antiviral treatment, if possible (AIII).
All HBsAG-positive patients awaiting chemotherapy or
immunosuppressive therapy should receive antiviral prophy-
laxis with a nucleoside analogue, regardless of HBV-DNA
levels. In anti-HBc positive patients with no detectable viral
replication (resolved HBV infection), there is a serious risk
(up to 50 %) of reverse seroconversion after allo-HCT [211].
These patients should be monitored for HBV replication on a
regular basis and receive preemptive antiviral treatment with
lamivudine (AII) or entecavir (AII) once HBV DNA levels
are positive (more details: Table 3). It is recommended that
antiviral treatment should be continued until at least 6 months
after the cessation of immunosuppression (BIII) [29].
Prophylactic treatment of anti-HBc-positive patients without
any viral load during the first months after allo-HCT is option-
al since no data are published in this patient population (CIII).
Hepatitis C prevention
Patients tested positive for HCV-RNA have a significantly
higher risk of developing sinusoidal obstruction syndrome
(SOS). Long after allo-HCT they suffer a higher rate of liver
fibrosis or cirrhosis [34]. Therefore, patients tested positive for
HCV-RNA should be considered (if time permitted) to receive
highly active antiviral treatment (BIIt) [212]. In allo-HCT,
data is lacking; however, Mahale et al. reported that patients
who have successfully eliminated HCV are not at risk of re-
activation at least after conventional chemotherapy [212].
Detailed therapy recommendations cannot be provided since
at this time many promising trials with new drugs are being
published demonstrating eradication of HCV [213].
Allo-HCT from an HCV-RNA-positive donor should be
avoided since the incidence of transmission remains high
(DII). If timing permitted and no alternative donor options
are available, the donor should be treated accordingly to pre-
vent hepatic complications (AIIt) [214].
Prevention of diseases caused by respiratory viruses
In recent years, an increasing number of reports on respiratory
viral infections after allo-HCT are noted, which are in part at-
tributable to improved diagnostic tools and better awareness.
RSV followed by influenza, parainfluenza, metapneumovirus,
and adenovirus are the main viruses causing severe diseases
[215]. These viruses can contribute significantly to morbidity
after allo-HCT; however, mortality rates seem to be mixed due
to heterogeneity of various risk situations [216]. The main rec-
ommendation is to avoid infections with these viruses through
adequate exposure prevention (AIII) [217, 218]. Visitors and
staff with signs and symptoms of respiratory infections must
avoid visiting the wards to prevent further disease (AIII).
Additionally, annual influenza vaccination is strongly recom-
mended for healthcare workers, all persons living with allo-
HCT candidates or patients to prevent transmission (AIII)
[219]. If vaccination was carried out during an influenza out-
break, a 2-week course of antiviral chemoprophylaxis could
follow until immune response is effective (BIII) [19, 220].
There is no published data confirming clinical efficacy of
prophylactic administration of respiratory syncytial virus
(RSV) immune globulin (RSVIG); therefore, this approach
is discouraged (DII) [221].
Intravenous immune globulin for prophylaxis
There is an ongoing controversy about the benefit, dosing, and
optimum preparation (hyperimmune or polyvalent) of intrave-
nous immune globulins (IVIG) in allo-HCT [222]. Older stud-
ies have demonstrated prevention of infection, interstitial
pneumonia (IP), or GVHD [223, 224]. Large meta-analyses
demonstrated no clinical benefit, except for a decrease of IP
and an increase of sinusoidal obstruction syndrome (SOS)
with high-dose IVIG [225, 226].
In a recent multicenter trial, 200 patients received different
doses of IVIG or placebo weekly starting day −7 till day +100,
but no differences were observed in regards to infections, in-
terstitial pneumonia, treatment-related mortality, and overall
survival. However, higher doses of immune globulin were
again associated with deleterious SOS [227]. Therefore, the
routine prophylactic substitution of immune globulin is not
recommended if the IgG level is >4 g/L (DI) [227, 228].
Nevertheless, a retrospective study reported patients with
severe hypogammaglobulinemia (e.g. IgG <4 g/L) were to be
at risk for decreased survival [229]. This compares well with
the IgG substitution recommendations by the IDSA [220] and
the guidelines for patients with the common variable immu-
nodeficiency (CVID) syndrome to substitute low-dose im-
mune globulin if IgG <4 g/l [230]. According to an analysis
by the Cochrane group, the use of IVIG may be considered in
patients with hypogammaglobulinemia associated with CLL
or multiple myeloma and recurrent infections. IVIG can sig-
nificantly decrease the number of infections [225, 226].
Therefore, immune globulin should be replaced in patients
with low serum IgG levels and recurrent infections associated
with hypogammaglobulinemia to lower the incidence of in-
fections (BIIt).
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Granulocyte transfusion for prophylaxis
A small matched pair analysis of nine neutropenic patients at
high risk for recurrence of a previous fungal infections after
allo-HCT demonstrated that prophylactic administration of
granulocyte transfusions could reduce the incidence and short-
en the duration of fever as well as the duration of neutropenia
compared to the control group [231]. Oza et al. performed a
Bbiological randomization^ in 151 stem cell recipients depen-
dent on ABO- and CMV-compatibility of their donor. There
was a significant decrease in the number of febrile days and
the use of intravenous antibiotics; however, no difference in the
length of hospital stay or 100-day survival was noted [232]. So
far, prophylactic granulocyte transfusion remains an experi-
mental approach and is considered more a therapeutic option.
Immunization (Tables 5 and 6)
Protection against vaccine-preventable infections should
be a part of the post-transplantationmedical caremanagement.
Ideally, trials should provide evidence for the protection
against diseases. However, a study powered for protective
efficacy is not necessary if a sponsor of a vaccine study can
justify the use of immunological data to predict protection
against infection [233]. If it is not feasible to perform an effi-
cacy study and there is no immunological correlation of pro-
tection, it may sometimes be justifiable to gauge the likely
efficacy of a vaccine by comparison of immunological re-
sponses with those seen in past studies of similar vaccines
with proven protective efficacy (e.g., acellular pertussis vac-
cines) [233].
In allo-HCT recipients, antibody titers against vaccine-
preventable infections decline, leading to an increased risk
of developing a disease [259]. For this reason, an early vacci-
nation schedule would be warranted. However, during the first
3 to 6 months after transplantation, a sufficient specific im-
mune system response to vaccination cannot be expected
[259]. Depending on different factors such as pre- and post-
transplant treatment, age, type of transplantation, or presence
of chronic GVHD, recovery of the immune system is delayed
[259]. Additionally, limited information about vaccine re-
sponse exists for patients after reduced-intensity conditioning
or with umbilical cord blood grafts. Administration of rituxi-
mab can suppress humoral immune response as long as
6 months after the last dose. Delayed vaccination schedules
should be considered in these patients (BIIt) [260–262].
Table 6 Immunization schedule
Vaccine SoR/
QoE
Relative to day of allo-HCT 12 months
after first
vaccination
Refresher Comments Ref
Day
+100
Month
+6
Month
+7
Month
+8
Pneumococcus AIIt X X X X Unclear Start with PCV13, after
12 months after first
vaccination the 23
valent polysaccharide
vaccine should be
used
[269–270, 308]
Influenza AII X X Annually [266, 271–276]
Polio
inactivateda
AII X X X X According to local
health advisory
a Combination
vaccine possible
[283–288, 309]
Pertussis
(acellular)a
AIII X X X X [277, 278, 309]
Diphtheria and
tetanus
toxoida
AII X X X X [279–282, 292, 309]
Haemophilus
influenzaea
BII X X X X [269, 284, 288–295, 311,
312]
Meningococcal
conjugate 4
valent and
serogroup B
BII X X None [295, 313–315]
TBE BIIt X X X 5 years [282, 316]
Hepatitis B CII X X Depending on titer Combination vaccine
possible (together
with HAV)
[298-299, 317–320]
Mumps,
measles,
rubella
BII Live attenuated vaccine
after 24 months
accordingly to the
rule mentioned
in Table 5
Unclear, depending
on immune
response
One dose is
recommended
[301–303, 321,
322]
Varicella zoster
virus (VZV)
BII [304–307, 323]
a combination vaccination possible
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Pneumococcal and meningococcal immunization with the
conjugated vaccine seems to provide a more stable immune
response than the polysaccharide-based vaccine in immature
or altered immune systems, but comparative trials are still
missing [263].
MMR (measles, mumps, rubella) and Varicella vaccines
are live attenuated vaccines that should not be given within
the first 2 years after transplantation or during active GVHD
(DIII). A significant risk of disease and side effects in the
immunocompromised patient were observed. However,
24 months after transplantation without evidence of chronic
GVHD and immunosuppression, MMR vaccine appears safe
to be administered (BIII).
Routine VZV-vaccination is currently not indicated in se-
ropositive patients for the prevention of herpes zoster (DIII).
A newer inactivated VZV vaccine is being developed provid-
ing adequate VZV-specific antibody titers in most patients
[264]. This new vaccine has the potential to change this rec-
ommendation in the future.
Additional immunizations against hepatitis A virus, human
papillomavirus, yellow fever, cholera, typhus, rotavirus, or
pre-exposure rabies virus vaccination are not routinely indicat-
ed in adults. Decision-making should follow the recommenda-
tions of general population and country-specific policy. Degree
of immune suppression against live attenuated vaccines espe-
cially in the allo-HCT population needs special attention.
Little is known whether vaccinations can induce GVHD,
since viral infections are known to do so [265]. On the other
hand, clinical data demonstrate response to vaccination de-
spite GVHD [266, 267]. A group of European experts pub-
lished results of a consensus conference on vaccination in
GVHD [268]. The conference attendees were more cautious
about immune suppression. In patients receiving prednisone
≥0.5 mg/kg bodyweight per day as part of a combination
therapy or a three-agent immunosuppressive treatment is giv-
en; vaccination may be postponed until immunosuppression is
reduced to a double combination or prednisone <0.5 mg/
kg bodyweight daily in order to achieve a better vaccine re-
sponse (BIII) [268].
Antibody titer testing prior to and after immunization
can be recommended for many vaccines. Decision-making
based on a titer is not recommended for all vaccinations
to document efficacy except for VZV, HAV, or HBV.
Basically, titer determination provides some insight on
vaccination success and should be considered as optional
(CIII). Testing for sufficient antibody response after im-
munization is indicated in hepatitis B one month or later
after the third vaccine dose (BIII). Revaccination with a
second series of hepatitis B vaccine should be considered
in non-responders (CIII).
In review of the available literature, clearly more studies
are needed to provide more information on the safety and
efficacy of vaccination schedules in allo-HCT.
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